Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting

International Journal of STD and AIDS

Volumn 16, Issue 4, 2005, Pages 307-313

  Klauke, Stephan ^a,g   Fischer, Harald ^b   Rieger, Armin ^c   Frühauf, Lukas ^d   Staszewski, Schlomo ^e   Althoff, Peter Henning ^f   Helm, Eilke Brigitte ^e  

^a HIV Schwerpunktpraxis   (Germany)

^b Internistische Praxis   (Germany)

^c Abteilung für Dermatologie   (Austria)

^d Internistische Praxis   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f Burgerhospital Frankfurt am Main   (Germany)

^g NONE   (Germany)

Author keywords

AIDS wasting syndrome; Bioelectrical impedance analysis; Recombinant human growth hormone

Indexed keywords

GROWTH HORMONE ANTIBODY; HUMAN GROWTH HORMONE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WATER; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; INJECTION SITE REACTION; LEAN BODY WEIGHT; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; MYELODYSPLASTIC SYNDROME; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WASTING SYNDROME; WEIGHT GAIN;

ADULT; AGED; BODY COMPOSITION; ELECTRIC IMPEDANCE; HAND STRENGTH; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 18744397564     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462053654177     Document Type: Article

References (22)

1. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR 1999;48:1-22
2. Centers for Disease Control Prevention. Revised classification system for HIV infections and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1987;36:1s-5
3. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retroviral 1998;18:80-5
4. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
5. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;31:803-5
6. Roubenoff R. Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am J Manag Care 2000;6:1003-16
7. Kotler DP, Tierney AR, Wang J, Pierson Jr RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-7
8. Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol 1991;11:331-41
9. Kotler DP, Wang J, Pierson R. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-65
10. Sluys TE, van der Ende ME, Swart GR, van der Berg JW, Wilson JH. Body composition in patients with acquired immunodeficiency syndrome: a validation study of bioelectric impedance analysis. J Parenter Enteral Nutr 1993;17:404-6
11. Brodie DA, Stewart AD. Body composition measurement: a hierarchy of methods. J Pediatr Endocrinol Metab 1999;12:801-16
12. Chertow GM. Estimates of body composition as intermediate outcome variables: are DEXA and BIA ready for prime time? J Ren Nutr 1999;9:138-41
13. Elia M, Ward LC. Joint symposium with the British Dietetic Association on implementing dietary change: theory and practice. Session 1: nutritional assessment. New techniques in nutritional assessment: body composition methods. Proc Nutr Soc 1999;58:33-8
14. Schwenk A, Beisenherz A, Römer K, Kremer G, Salzberger B, Elia M. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. Am J Clin Nutr 2000;72:496-501
15. Ott M, Fischer H, Polat H, et al. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retroviral 1995;9:20-5
16. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:43-8
17. Paton NI, Macallan DC, Jebb SA, et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic Syndr Hum Retroviral 1997;14:119-27
18. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000;75:386-94
19. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment diagnosis, and treatment. AIDS Patient Care STDS 2001;15:411-23
20. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125:873-82
21. Sattler FR, Jaque SV, Schroeder ET, et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999;84:1268-76
22. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62